Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Nov
10
Today In Oncology
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
Two Forever Chemicals Associated Higher Risk of ER-Negative Breast Cancer
Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies
Extended Follow-up of Nivolumab Ipilimumab for Localized dMMR MSI-H Gastric GEJ Cancer
Claudia Henschke, PhD, MD Finding Lung Cancer in Time
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo